Skip to main content
Beth Israel Deaconess Medical Center
Primary menu
  • Home
  • Our Team
  • Research
  • Fellowship & Education
  • Publications
  • News and Archives

In H pylori infection, vonoprazan plus high-dose amoxicillin was noninferior to B-quadruple therapy for eradication.

Flynn, Duncan J, and Joseph D Feuerstein. 2023. “In H Pylori Infection, Vonoprazan Plus High-Dose Amoxicillin Was Noninferior to B-Quadruple Therapy for Eradication.”. Annals of Internal Medicine 176 (5): JC54.
Publisher's Version

Abstract

Qian HS, Li WJ, Dang YN, et al. Ten-day vonoprazan-amoxicillin dual therapy as a first-line treatment of Helicobacter pylori infection compared with bismuth-containing quadruple therapy. Am J Gastroenterol. 2023;118:627-634. 36729890.

Last updated on 07/28/2025
PubMed

Selected Publications

  • Mistakes in therapeutic drug monitoring of biologics in IBD and how to avoid them
  • Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn's disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial).
  • Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
  • A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease.
  • Higher Postinduction Infliximab Concentrations Are Associated With Improved Clinical Outcomes in Fistulizing Crohn's Disease: An ACCENT-II Post Hoc Analysis.
  • Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
More
Contact Us

330 Brookline Avenue

Boston, MA, 02215

Powered byOpenScholar®Admin Login